Yen CL, Fan PC, Lin MS, et al. - This national cohort study was conducted to compare results in advanced chronic kidney disease (CKD) patients managed with fenofibrate, statins, a combination of both, and none of these. Taiwan’s National Health Insurance Research Database was utilized for this purpose. Participants included aged > 20 years patients with advanced CKD, these were further split into 4 categories based on treatment. A lower risk of cardiovascular (CV) death was observed in the fenofibrate and statin groups vs the nonuser group. The lowest incidence of permanent dialysis was also noted in the fenofibrate group. Overall, it was inferred that continuing treatment with fenofibrate may offer a protective impact on CV results equal to that of statins as well as it may result in a further delay in the requirement for permanent dialysis in patients suffering from advanced CKD. Additional benefits may be conferred by the combination of fenofibrate and high intensity statins.